Glioblastoma in adults

Alba A. Brandes, Alicia Tosoni, Enrico Franceschi, Michele Reni, Gemma Gatta, Charles Vecht

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Glioblastoma (GBM) is the most malignant among astrocytic tumours and is associated with a poor prognosis. Age, performance status, mini-mental status examination score, methylation status of methylguanine methyltransferase promoter and extent of surgery constitute the main prognostic factors. Surgery aimed to complete resection should be the first therapeutic modality in the management of glioblastoma. However, complete resection is virtually impossible due to infiltrative nature of this disease and relapse is almost inevitable. Postoperative concomitant chemo-radiation is the standard treatment and consists of 60 Gy of external-beam radiotherapy (to be delivered to a target volume including a 2-3 cm ring of tissue surrounding the perimeter of the contrast enhancing lesion on pre-operative CT/MRI scans) plus temozolomide (TMZ) administered concomitantly (75 mg/m2 daily) and after radiotherapy (150-200 mg/m2, for 5 days every 4 weeks). At time of recurrence/progression, a nitrosourea-based chemotherapy constitutes a reasonable option, as well as a temozolomide re-challenge for patients without progression during prior temozolomide treatment.

Original languageEnglish
Pages (from-to)139-152
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Volume67
Issue number2
DOIs
Publication statusPublished - Aug 2008

Fingerprint

temozolomide
Glioblastoma
Radiotherapy
Recurrence
Methyltransferases
Methylation
Therapeutics
Magnetic Resonance Imaging
Radiation
Drug Therapy
Neoplasms

Keywords

  • Chemotherapy
  • Glioblastoma
  • Radiotherapy
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Glioblastoma in adults. / Brandes, Alba A.; Tosoni, Alicia; Franceschi, Enrico; Reni, Michele; Gatta, Gemma; Vecht, Charles.

In: Critical Reviews in Oncology/Hematology, Vol. 67, No. 2, 08.2008, p. 139-152.

Research output: Contribution to journalArticle

Brandes, AA, Tosoni, A, Franceschi, E, Reni, M, Gatta, G & Vecht, C 2008, 'Glioblastoma in adults', Critical Reviews in Oncology/Hematology, vol. 67, no. 2, pp. 139-152. https://doi.org/10.1016/j.critrevonc.2008.02.005
Brandes, Alba A. ; Tosoni, Alicia ; Franceschi, Enrico ; Reni, Michele ; Gatta, Gemma ; Vecht, Charles. / Glioblastoma in adults. In: Critical Reviews in Oncology/Hematology. 2008 ; Vol. 67, No. 2. pp. 139-152.
@article{a73c558fef1b42d6b2533c13f678f16a,
title = "Glioblastoma in adults",
abstract = "Glioblastoma (GBM) is the most malignant among astrocytic tumours and is associated with a poor prognosis. Age, performance status, mini-mental status examination score, methylation status of methylguanine methyltransferase promoter and extent of surgery constitute the main prognostic factors. Surgery aimed to complete resection should be the first therapeutic modality in the management of glioblastoma. However, complete resection is virtually impossible due to infiltrative nature of this disease and relapse is almost inevitable. Postoperative concomitant chemo-radiation is the standard treatment and consists of 60 Gy of external-beam radiotherapy (to be delivered to a target volume including a 2-3 cm ring of tissue surrounding the perimeter of the contrast enhancing lesion on pre-operative CT/MRI scans) plus temozolomide (TMZ) administered concomitantly (75 mg/m2 daily) and after radiotherapy (150-200 mg/m2, for 5 days every 4 weeks). At time of recurrence/progression, a nitrosourea-based chemotherapy constitutes a reasonable option, as well as a temozolomide re-challenge for patients without progression during prior temozolomide treatment.",
keywords = "Chemotherapy, Glioblastoma, Radiotherapy, Review",
author = "Brandes, {Alba A.} and Alicia Tosoni and Enrico Franceschi and Michele Reni and Gemma Gatta and Charles Vecht",
year = "2008",
month = "8",
doi = "10.1016/j.critrevonc.2008.02.005",
language = "English",
volume = "67",
pages = "139--152",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Glioblastoma in adults

AU - Brandes, Alba A.

AU - Tosoni, Alicia

AU - Franceschi, Enrico

AU - Reni, Michele

AU - Gatta, Gemma

AU - Vecht, Charles

PY - 2008/8

Y1 - 2008/8

N2 - Glioblastoma (GBM) is the most malignant among astrocytic tumours and is associated with a poor prognosis. Age, performance status, mini-mental status examination score, methylation status of methylguanine methyltransferase promoter and extent of surgery constitute the main prognostic factors. Surgery aimed to complete resection should be the first therapeutic modality in the management of glioblastoma. However, complete resection is virtually impossible due to infiltrative nature of this disease and relapse is almost inevitable. Postoperative concomitant chemo-radiation is the standard treatment and consists of 60 Gy of external-beam radiotherapy (to be delivered to a target volume including a 2-3 cm ring of tissue surrounding the perimeter of the contrast enhancing lesion on pre-operative CT/MRI scans) plus temozolomide (TMZ) administered concomitantly (75 mg/m2 daily) and after radiotherapy (150-200 mg/m2, for 5 days every 4 weeks). At time of recurrence/progression, a nitrosourea-based chemotherapy constitutes a reasonable option, as well as a temozolomide re-challenge for patients without progression during prior temozolomide treatment.

AB - Glioblastoma (GBM) is the most malignant among astrocytic tumours and is associated with a poor prognosis. Age, performance status, mini-mental status examination score, methylation status of methylguanine methyltransferase promoter and extent of surgery constitute the main prognostic factors. Surgery aimed to complete resection should be the first therapeutic modality in the management of glioblastoma. However, complete resection is virtually impossible due to infiltrative nature of this disease and relapse is almost inevitable. Postoperative concomitant chemo-radiation is the standard treatment and consists of 60 Gy of external-beam radiotherapy (to be delivered to a target volume including a 2-3 cm ring of tissue surrounding the perimeter of the contrast enhancing lesion on pre-operative CT/MRI scans) plus temozolomide (TMZ) administered concomitantly (75 mg/m2 daily) and after radiotherapy (150-200 mg/m2, for 5 days every 4 weeks). At time of recurrence/progression, a nitrosourea-based chemotherapy constitutes a reasonable option, as well as a temozolomide re-challenge for patients without progression during prior temozolomide treatment.

KW - Chemotherapy

KW - Glioblastoma

KW - Radiotherapy

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=45949107833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45949107833&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2008.02.005

DO - 10.1016/j.critrevonc.2008.02.005

M3 - Article

C2 - 18394916

AN - SCOPUS:45949107833

VL - 67

SP - 139

EP - 152

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -